Table 3 Univariate and multivariate analyses of prognostic factors for overall survival in patients with neoadjuvant chemotherapy

Age(> 60 vs. ≤60 years)

1.184(0.813–1.724)

0.378

1.398(0.8869–2.251)

0.168

Sex (male vs. female)

1.293(0.863–1.936)

0.213

0.788(0.472–1.313)

0.360

Primary tumor location (rectum vs. colon)

1.037(0.725–1.484)

0.841

1.146(0.725–1.81)

0.560

Primary T stage (4 vs. 1–3)

0.999(0.700-1.427)

0.998

0.909(0.579–1.428)

0.679

Nodal metastases (positive vs. negative)

1.778(1.227–2.578)

0.002

1.889(1.298–2.748)

0.001

1.44(0.902–2.299)

0.127

Primary tumor differentiation (poor vs. well to moderate)

1.158(0.779–1.721)

0.467

1.581(0.973–2.57)

0.064

Timing of metastasis

(synchronous vs. metachronous)

0.74(0.49–1.118)

0.153

0.713(0.427–1.189)

0.195

RECIST response (SD/PD vs. PR)

1.097(0.76–1.583)

0.621

0.988(0.618–1.581)

0.960

Preoperative CEA (> 5 vs. ≤ 5 ng/mL)

1.333(0.922–1.927)

0.127

0.576(0.332–1.001)

0.051

Preoperative CA19-9 (> 35 vs. ≤ 35 U/mL)

1.083(0.714–1.643)

0.708

0.768(0.458–1.289)

0.318

Postoperative adjuvant therapy (yes vs. no)

1.539(1.034–2.291)

0.033

1.578(1.057–2.356)

0.026

1.557(0.997–2.431)

0.051

TBS (> 3 vs. ≤ 3)

1.18(0.8-1.741)

0.404

1.66(0.966–2.854)

0.067

Tumor distribution (bilobar vs. unilobar)

1.413(0.99–2.018)

0.057

1.652(1.048–2.603)

0.031

Postoperative chemotherapy (yes vs. no)

1.043(0.684-1,591)

0.845

1.233(0.716–2.123)

0.450